Evolus Inc Stock Buy Hold or Sell Recommendation

EOLS Stock  USD 13.97  0.24  1.69%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Evolus Inc is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Evolus Inc given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Evolus Inc, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Evolus Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
Note, we conduct extensive research on individual companies such as Evolus and provide practical buy, sell, or hold advice based on investors' constraints. Evolus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Execute Evolus Buy or Sell Advice

The Evolus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Evolus Inc. Macroaxis does not own or have any residual interests in Evolus Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Evolus' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell EvolusBuy Evolus
Cautious Hold

Market Performance

Very WeakDetails

Volatility

Somewhat reliableDetails

Hype Condition

StaleDetails

Current Valuation

Fairly ValuedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Responds to the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

UnavailableDetails
For the selected time horizon Evolus Inc has a Mean Deviation of 2.95, Standard Deviation of 4.92 and Variance of 24.17
Our trade advice tool can cross-verify current analyst consensus on Evolus Inc and to analyze the company potential to grow in the current economic cycle. To make sure Evolus is not overpriced, please confirm all Evolus Inc fundamentals, including its current ratio, total asset, and the relationship between the net income and price to earnings to growth . Given that Evolus Inc has a price to earning of (5.55) X, we urge you to verify Evolus Inc market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Evolus Trading Alerts and Improvement Suggestions

Evolus Inc generated a negative expected return over the last 90 days
Evolus Inc has high historical volatility and very poor performance
The company reported the previous year's revenue of 202.09 M. Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 173.69 M.
Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51.
Over 79.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Gill David N of 8293 shares of Evolus subject to Rule 16b-3

Evolus Returns Distribution Density

The distribution of Evolus' historical returns is an attempt to chart the uncertainty of Evolus' future price movements. The chart of the probability distribution of Evolus daily returns describes the distribution of returns around its average expected value. We use Evolus Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Evolus returns is essential to provide solid investment advice for Evolus.
Mean Return
-0.14
Value At Risk
-4.93
Potential Upside
5.36
Standard Deviation
4.92
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Evolus historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Evolus Stock Institutional Investors

The Evolus' institutional investors refer to entities that pool money to purchase Evolus' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
Shares
Millennium Management Llc2024-09-30
M
Schroder Investment Management Group2024-09-30
M
Morgan Stanley - Brokerage Accounts2024-09-30
M
Lord, Abbett & Co Llc2024-09-30
995.4 K
Boothbay Fund Management, Llc2024-09-30
983.7 K
D. E. Shaw & Co Lp2024-09-30
970.3 K
Assenagon Asset Management Sa2024-09-30
955.6 K
Rice Hall James & Associates, Llc2024-09-30
904.9 K
Nuveen Asset Management, Llc2024-09-30
897.1 K
Perceptive Advisors Llc2024-09-30
5.4 M
Tang Capital Management Llc2024-09-30
4.8 M
Note, although Evolus' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Evolus Cash Flow Accounts

202020212022202320242025 (projected)
Change In Cash(7.3M)43.7M(11.7M)8.9M8.0M12.7M
Net Borrowings70.7M39.5M(27.6M)(500K)(450K)(427.5K)
Free Cash Flow(61.0M)(34.4M)(11.7M)(35.6M)(32.1M)(33.7M)
Depreciation7.7M6.3M4.5M5.9M6.7M3.7M
Capital Expenditures3.1M970K2.9M1.6M1.9M1.6M
Net Income(163.0M)(46.8M)(74.4M)(61.7M)(55.5M)(58.3M)
Change To Netincome(990K)59.2M17.4M18.2M20.9M14.8M
Change To Inventory4.5M(3.0M)(10.7M)4.2M4.8M5.1M
Investments12.2M5M(2.9M)(1.6M)(1.9M)(2.0M)
Other Non Cash Items51.3M9.1M84.6M11.2M10.1M9.6M
End Period Cash Flow102.6M146.3M53.9M62.8M72.3M89.4M

Evolus Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Evolus or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Evolus' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Evolus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.21
β
Beta against Dow Jones0.92
σ
Overall volatility
5.07
Ir
Information ratio -0.04

Evolus Volatility Alert

Evolus Inc exhibits very low volatility with skewness of 2.68 and kurtosis of 17.41. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Evolus' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Evolus' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Evolus Fundamentals Vs Peers

Comparing Evolus' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Evolus' direct or indirect competition across all of the common fundamentals between Evolus and the related equities. This way, we can detect undervalued stocks with similar characteristics as Evolus or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Evolus' fundamental indicators could also be used in its relative valuation, which is a method of valuing Evolus by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Evolus to competition
FundamentalsEvolusPeer Average
Return On Equity-8.62-0.31
Return On Asset-0.0993-0.14
Profit Margin(0.22) %(1.27) %
Operating Margin(0.21) %(5.51) %
Current Valuation929.44 M16.62 B
Shares Outstanding63.32 M571.82 M
Shares Owned By Insiders12.30 %10.09 %
Shares Owned By Institutions79.32 %39.21 %
Number Of Shares Shorted5.93 M4.71 M
Price To Earning(5.55) X28.72 X
Price To Book152.77 X9.51 X
Price To Sales3.56 X11.42 X
Revenue202.09 M9.43 B
Gross Profit173.69 M27.38 B
EBITDA(41.81 M)3.9 B
Net Income(61.69 M)570.98 M
Cash And Equivalents84.48 M2.7 B
Cash Per Share1.51 X5.01 X
Total Debt126.55 M5.32 B
Debt To Equity1.59 %48.70 %
Current Ratio2.60 X2.16 X
Book Value Per Share0.09 X1.93 K
Cash Flow From Operations(34.01 M)971.22 M
Short Ratio8.50 X4.00 X
Earnings Per Share(0.91) X3.12 X
Price To Earnings To Growth(0.52) X4.89 X
Target Price23.71
Number Of Employees32218.84 K
Beta1.32-0.15
Market Capitalization884.6 M19.03 B
Total Asset189 M29.47 B
Retained Earnings(558.98 M)9.33 B
Working Capital64.13 M1.48 B
Note: Acquisition by Gill David N of 8293 shares of Evolus subject to Rule 16b-3 [view details]

Evolus Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Evolus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Evolus Buy or Sell Advice

When is the right time to buy or sell Evolus Inc? Buying financial instruments such as Evolus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Evolus in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sector ETFs Thematic Idea Now

Sector ETFs
Sector ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sector ETFs theme has 439 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sector ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Evolus Stock Analysis

When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.